Further analysis identified its target within the enzyme catalytic domain, where CU‐3 competitively inhibits the affinity of DGKα for ATP, and validated its potential for improving cancer cell apoptosis and increasing IL‐2 production in T cells, suggesting a dual role in cancer therapy for this compound. This evidence concerns the gene DGKA and cancer.